Topic summary

Interim analyses and stopping rules

Evidence › Trials intention to treat surrogate endpoints open label discontinuation & dropout randomised trial

This is a generated summary. It shows the 5 most-liked posts from a topic of 30, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

endpoint_lineTL3Regular22 Nov 2025 · edited#5

My understanding of interim analyses and stopping rules is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.

26 likes 8mo

j.bhattacharyaTL224 Feb 2026#14

Helpful, and easy to find again, which is half of what a good reply is.

27 likes 5mo

g.bakkenTL22 Apr 2026#18

Nothing to add, except that this is the answer I would give if asked.

19 likes 4mo

e.ferreiraTL3Regular9 Jun 2026#26

An update on my earlier interim analyses and stopping rules post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.

26 likes 2mo

d.vukovicTL212 Jul 2026 · edited#30

Two questions I would want answered before drawing anything from the interim analyses and stopping rules data above: how were the cases selected, and what happened to the ones that dropped out.

19 likes 16d

Read the full topic (30 posts)

Promoted into the documentation commons. The content of this topic is maintained at SCALE — trial digest, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Adjudicated events and why the definition matters Evidence › Trials estimand intention to treat discontinuation & dropout surrogate endpoints Under review On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. A follow-up question about adjudicated events that I did not know to ask the first time.…		2	4.5k	2mo
Non-inferiority margins: how they are chosen and how they are abused Evidence › Trials open label surrogate endpoints estimand intention to treat Posting this under the heading it deserves: Non-inferiority margins: how they are chosen and how they are abused Everything below is what sits behind that. A question about non-inferiority margins that I…	+42	46	10k	5mo
Composite endpoints and the component doing the work Evidence › Trials randomised trial surrogate endpoints open label discontinuation & dropout Solved Under review Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…	+3	7	33k	13h
Primary endpoint hierarchies and why order matters — one year on Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial Solved On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…	+56	61	37k	11h
Revisiting: Primary endpoint hierarchies and why order matters Evidence › Trials estimand surrogate endpoints discontinuation & dropout intention to treat Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. I was wrong about Primary endpoint hierarchies in a thread…	+21	25	46k	3mo

Related topics — sharing the tags intention to treat, surrogate endpoints, open label

Topic	Participants	Replies	Views	Activity
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Compounds › Semaglutide SELECT trial STEP programme effect size randomised trial Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first…		2	39k	6mo
SNAC and the mechanism of oral peptide absorption — the long version Compounds › Oral incretins oral semaglutide randomised trial orforglipron SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. Question about what the published evidence for this…	+32	36	6.8k	16mo
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…	+27	31	17k	25d
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on…		2	17k	6h
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Evidence › Journal club estimand effect size risk of bias journal club Solved On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before posting;…	+71	76	52k	21mo